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Abstract 
 
Wilms’ tumours (WT) are large heterogeneous tumours, which typically consist of a mixture 
of histological cell types, along with regions of chemotherapy induced regressive change and 
necrosis. The predominant cell type in a WT is assessed histologically following 
nephrectomy, and used to assess the tumour subtype and potential risk. The purpose of this 
study was to develop a mathematical model to identify sub-regions within WTs with distinct 
cellular environments in vivo, determined using Apparent Diffusion Coefficient (ADC) values 
from diffusion-weighted imaging (DWI). We recorded WT subtype from the histopathology of 
32 tumours resected in patients who received DWI prior to surgery, after pre-operative 
chemotherapy had been administered. In 23 of these tumours, DWI data were also available 
prior to chemotherapy. Histograms of ADC values were analysed using a multi-Gaussian 
model fitting procedure, which identified ‘sub-populations’ with distinct cellular environments 
within the tumour volume. The mean and lower quartile ADC values of the predominant 
viable-tissue sub-population (ADC1MEAN, ADC1LQ), along with the same parameters from the 
entire tumour volume (ADC0MEAN, ADC0LQ), were tested as predictors of WT subtype. ADC1LQ 
from the multi-Gaussian model was the most effective parameter for stratification of WT 
subtype, with significantly lower values observed in high-risk blastemal-type WTs compared 
to intermediate risk stromal, regressive and mixed-type (p<0.05). No significant difference in 
ADC1LQ was found between blastemal-type WTs and intermediate risk epithelial-type. The 
predominant viable tissue sub-population in every stromal-type WT underwent a positive 
shift in ADC1MEAN after chemotherapy.  Our results suggest that our multi-Gaussian model is 
a useful tool for differentiating distinct cellular regions within WTs, which helps to identify the 
predominant histological cell type in the tumour in vivo.  This shows potential for improving 
the risk-based stratification of patients at an early stage, and for guiding biopsies to target 
the most malignant part of the tumour. 
 
Introduction 
Malignant renal tumours comprise 6% of all childhood cancers. Wilms’ tumour (WT), or 
nephroblastoma, is by far the most frequent type, accounting for over 90% of renal tumours, 
of which approximately 7% are bilateral [1]. In Europe, WT is treated with pre-operative 
chemotherapy, followed by surgery. The aim of chemotherapy is to reduce the tumour size 
to facilitate subsequent surgery, decrease the risk of intra-operative tumour rupture, and to 
downstage the tumour to reduce post-operative chemotherapy. Radiological assessment of 
chemotherapy response has traditionally been measured using change in tumour volume on 
imaging. However, this can be unreliable in the presence of substantial necrosis, and tissue 
differentiation may occur despite an increase in volume [2]. Furthermore, tumours which 
shrink in volume may still be composed predominantly of malignant cells [3], [4].       
After chemotherapy, a full or partial nephrectomy is performed and the excised tumour is 
classified histologically. Traditionally, WT are divided into two groups: favourable or 
anaplastic histology, with the latter demonstrating nuclear enlargement, nuclear atypia, and 
irregular mitotic figures. The frequency of anaplasia is about 5%, and these patients are 
considered particularly high-risk, with an estimated recurrence free survival rate of 40-50% 
[5], [6]. WTs are further classified according to the predominant features of the tissue after 
chemotherapy. If >66% of the tissue has undergone chemotherapy-induced change, the 
tumour is classified as regressive, or completely necrotic if no viable tumour tissue remains. 
If <66% of the tumour shows chemotherapy induced change, and one of stromal, epithelial 
or blastemal cells represent >66% of the viable tissue, the tumour is classified according to 
the predominant cellular subtype; otherwise, the tumour is classified as mixed type [7].  
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Patients with epithelial, stromal, mixed and regressive WTs generally have very favourable 
outcomes (>89% recurrence free survival after 4 years [8]), and are classified according to 
the International Society of Pediatric Oncology (SIOP) protocol as intermediate risk [7], [9]. 
Patients with blastemal WTs have a less favourable outcome (62% recurrence free survival 
rate after 5 years [10]), and are classified as high-risk.  
 
Although the overall survival rate in most WT subtypes is very high, patients are vulnerable 
to the late effects of treatment, with nearly one quarter reporting a significant chronic health 
condition by 25 years of follow up [11]. As such, the focus of management in this disease 
has shifted to improving risk-based stratification, to maintain excellent outcomes in low risk 
patients while decreasing the toxicity and burden of treatment. Conversely, it is important to 
identify patients with high risk tumours early, as these may benefit from intensified therapy 
[12].  This would require early identification of WT subtype, and a good understanding of 
how each subtype responds to chemotherapy. However, at present WT subtype can only be 
determined by histological assessment of the tumour tissue, after pre-operative 
chemotherapy and nephrectomy. Given the heterogeneous nature of WTs, needle biopsies 
are susceptible to sampling errors [13], and therefore non-invasive imaging techniques have 
a vital role to play in both early patient risk-stratification and guiding biopsies to focus on the 
most malignant part of the tumour. 
Although Computed tomography (CT) is often used for imaging and staging of WT, magnetic 
resonance imaging (MRI) offers superior spatial resolution and tissue contrast, does not use 
ionizing radiation, and is therefore the preferred imaging modality. Diffusion-weighted 
imaging (DWI) is an MRI technique which measures the apparent diffusion coefficient (ADC) 
of water molecules in the tissue, which acts as a surrogate biomarker of cellular density [14]. 
Advances in MR imaging technology in recent years have led to increasing use of DWI in 
extra-cranial imaging applications, and ADC values have been shown to be useful in 
characterising tumours in the breast [15], liver [16], prostate [17], and kidney [18], [19]. 
However, the use of DWI in WT is relatively unexplored. Humphries et al. reported a 
negative correlation between ADC and histological features (cell density) in a range of 
extracranial mass lesions (three of which were WTs) [14]. McDonald et al. examined 
patterns of shift in ADC histograms in abdominal tumours during chemotherapy (six of which 
were WTs), however, due to the small cohort used in this study, no attempt was made to 
differentiate WT subtypes [2]. Furthermore, it is common for the mean ADC value within a 
tumour to be reported, however, as WTs are heterogeneous entities, a mixture of cellular 
environments can be present within a single WT, in which case a single mean is not 
representative of the underlying tissue. An approach taken by others is to define ROIs in 
homogenous regions of the tumour, often only in a single slice – however, this approach can 
be subjective, and does not cover the entire tumour volume, and is therefore prone to 
sampling errors. In this work we developed a mathematical model which identifies ‘sub-
populations’ in histograms of ADC values which represent distinct cellular environments, 
throughout the entire tumour volume. We aimed to use this model to: (a) distinguish viable 
and non-viable tumour tissue, (b) identify the most prominent viable tissue sub-population, 
and (c) explore the link between the ADC values in this sub-population with histological 
assessment of the tumour. 
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Materials and Methods 
 
Patients 
 
Data were collected retrospectively from routine healthcare records of children who were 
referred for MRI assessment of primary abdominal solid tumours at our institution between 
January 2006 and October 2013. Local institutional research office approval was granted for 
this retrospective case note and imaging review. Only children diagnosed with WT, who 
received DWI prior to nephrectomy (following pre-operative chemotherapy) were included in 
this study. Exclusion criteria were tumours where the largest area on a single imaging slice 
was <3cm2, and where specimens were unavailable for histopathological assessment. A 
total of 26 patients met the inclusion criteria for this study, 6 of whom had independently 
histologically-classified bilateral tumours, bringing the total number of tumours to 32. In 23 of 
these tumours, DWI data were also acquired prior to chemotherapy. Children were awake, 
sedated or under general anaesthesia during the scan, depending on their age. Histological 
sections from surgically resected tumours were examined and reported according to current 
SIOP practice guidelines, in which tumours were classified according to the predominant 
histological cell type in the tumour tissue. 
 
 
MRI 
 
All scans were performed on a 1.5 T Siemens Magnetom Avanto scanner (Siemens, 
Erlangen, Germany), equipped with 40 mT/m gradients. A suitably sized multichannel body 
coil was chosen based on patient size, with a preference for the smallest coil combination 
that covered the whole abdomen and pelvis.  
 
Conventional imaging sequences were acquired in each patient according to our institution’s 
clinical protocol, which included coronal and axial 2D dual-echo short-tau inversion recovery 
(STIR), Axial T2-weighted fast spin-echo, and fat-suppressed T1w images before and after 
intravenous administration of gadolinium-based contrast (details in [2]). In addition, diffusion-
sensitised 2D single-shot echo-planar imaging was performed in the axial plane during free 
breathing. This was planned using the conventional sequences, by centering the acquisition 
slab on the tumour and using up to 19 sections to cover the entire tumour volume. Scan 
parameters were: slice thickness, 6 mm; intersection gap, 1.2–2.4 mm, TR/TE, 2,600 ms/89 
ms; field of view, 350 mm with a rectangular factor of 75%; echo-planar readout with matrix 
of 128 and 96 phase-encoding steps; receive bandwidth, 1,500 Hz/pixel; parallel imaging 
factor 2. We used signal averaging of six acquisitions and diffusion-sensitising gradients in 
three orthogonal planes with b-values of 0, 500 and 1,000 s/mm2. Fat signal was suppressed 
using a frequency-selective radio-frequency preparation pulse. Total acquisition time for this 
sequence was 5.3 min, and diffusion-weighted images were always acquired prior to 
administration of gadolinium-based contrast material.  
 
Post Processing 
 
All data analysis was performed using Matlab R2014a (MathWorks Inc., Natick, MA). ADC 
maps were collected in each patient, which were produced by calculation of the slope of the 
natural logarithm of mean signal intensity (over three orthogonal planes) vs. b-value.  
Regions of interest (ROIs) were drawn around the perimeter of each tumour on every b0 
(non-diffusion weighted) imaging slice, provided the tumour area was greater than 3 cm2, to 
avoid partial volume artefacts. All ROIs were either drawn or checked by a consultant 
radiologist with 12 years experience in paediatric radiology. Conventional MR images 
acquired during the same scan session were used to guide tracing of the tumour outline.  
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T1w images acquired both pre- and post- gadolinium contrast agent injection were not 
available in all patients, and in some others these images were rejected when they were 
severely degraded by respiratory motion artefacts; overall 15 patients had good quality pre- 
and post-gadolinium T1w images. In these patients, a further ‘viable tumour’ mask was 
created as follows: firstly, signal intensity from pre-gadolinium T1w images was subtracted 
from post-gadolinium T1w images. The subtracted set was then thresholded to include only 
voxels with a value above that of the erector spinae muscles (similar to [2]) – voxels with 
signal intensity below this threshold were classified as non-enhancing / necrotic regions (i.e. 
regions in which the uptake of gadolinium is minimal). MedInria software (Inria, Le Chesnay, 
France) was then used to register the viable tumour tissue mask to ADC maps using a linear 
registration. This mask was also inverted to provide a non-viable tumour tissue mask.   
 
 
Multi-Gaussian model fitting 
 
Normalised histograms of ADC values from the entire tumour ROI in each patient (and at 
each time point where DWI was also performed prior to chemotherapy) were produced, with 
number of bins = log2(N) + 1, where N=number of voxels within the ROI [20]. To model sub-
populations of ADC values within the tumour, a step-wise multi-Gaussian model fitting 
technique was used. This employed a non-linear least squares trust region algorithm [21] to 
fit the histogram to the following equation: 
 
𝑦 = ∑ 𝑎𝑘 ∙ 𝑒
[−(
𝑥−𝜇𝑘
𝑐𝑘
)
2
]
𝑘𝑚𝑎𝑥
𝑘=1
 
(1) 
 
 
where y = vector of normalised frequency values from the histogram, kmax = number of 
Gaussian components (kmax = {1,2,3}), ak, μk and ck = amplitude, mean and √2*standard 
deviation of the kth component Gaussian respectively, and x = vector of ADC bin centres 
from the normalised histogram. Initially three Gaussian distributions were fit to the ADC 
histogram (kmax=3), using the ‘fit’ function in Matlab, which provided fitted values of the 
mean, standard deviation and amplitude of each distribution, as well as the 95% confidence 
interval (CI) for each fitted parameter. If the CI surrounding the means of any of the 
distributions overlapped, the model was rejected. In this case, a two Gaussian model was 
used (kmax=2), and again, if the CI of the two means overlapped, the process was repeated 
with a single Gaussian model (kmax=1).  
 
Following model selection, the Mahalanobis distance [24] between the ADC value in each 
voxel within the tumour ROI and each of the fitted Gaussian components for that tumour was 
calculated (denoted mk for the Mahalanobis distance to the kth Gaussian component). For 
visualisation purposes, the Mahalanobis distance to each component Gaussian (ranging 
from m1 for the distance to the lowest-ADC component, to m3 for the distance to highest-
ADC component, if kmax=3) was normalised to the sum of all the Mahalanobis distances in 
that voxel (e.g. m1n = m1/(m1+m2+m3) if kmax=3, or m1n = m1/(m1+m2) if kmax=2). For tumours in 
which kmax=3, values of 1-m1n, 1-m2n and 1-m3n were assigned to the red, green and blue 
colour channels of the ADC image respectively, so that voxels closest to the lowest-ADC 
peak appeared red, voxels closest to the middle-ADC peak appeared green, and voxels 
closest to the highest-ADC peak appeared blue.  Similarly if kmax=2, just the red and green 
channels were used, with voxels closest to the lower-ADC peak appearing red, and voxels 
closest to the higher-ADC peak appearing green. This process is illustrated for an example 
patient in Figure 1.   
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Identification of non-viable tissue in ADC maps  
 
ADC values from voxels which were classified as containing either viable or non-viable 
tumour tissue using the viable/non-viable tissue masks (see 2.3 Post Processing) were 
pooled across the cohort. ROC analysis was then used to determine the optimum upper 
threshold for viable tumour tissue ADC values (ADCviable) – ADC values above this were 
classified as representing non-viable tissue. This threshold value was then used in every 
patient to classify any ADC subpopulation centred above ADCviable as a ‘non-viable’ 
subpopulation.  
 
 
Differentiation of Wilms tumour subtypes 
 
ADC histograms from the post-chemotherapy scans were used for comparison with the 
histological assessment of the tumour, as these were most representative of the final 
excised tissue (the composition of the tumour tissue will generally change considerably 
during chemotherapy [2], [8], so pre-chemotherapy ADC data were not used in this part of 
the analysis). As histological quantification of stromal, blastemal and epithelial cells was only 
performed in viable tumour tissue, sub-populations from the multi-Gaussian model centred 
on an ADC value greater than ADCviable were excluded. Following this, the sub-population 
within the ADC histogram with the greatest peak height was identified (referred to henceforth 
as ADC1) - this represented the predominant viable tissue in the tumour, which is most 
representative of the tissue that is assessed histologically. The following summary 
parameters were evaluated for this sub-population: the mean ADC value (ADC1MEAN), and 
the lower quartile ADC value (ADC1LQ). The lower quartile ADC value was chosen to capture 
regions of high cellularity within the predominant sub-population, and is in accordance with 
several other studies investigating ADC histogram properties for differentiation of tumour 
grade [25], [26]. Note basing an analysis on the minimum ADC value is unreliable, as an 
entire tumour is classified based on the value in a single voxel.  
 
For comparison, the same parameters from the ‘raw’ ADC histogram (ADC0MEAN and 
ADC0LQ), representing the entire tumour volume without the multi-Gaussian model being 
applied, were also calculated. After confirming the data were normally distributed using 
Lilliefors test (5% significance level), a one-way ANOVA was used to test for significant 
differences in these summary parameters (ADC1MEAN, ADC1LQ, ADC0MEAN and ADC0LQ) 
across WT subtypes, followed by a Tukey-Kramer posthoc test to determine which subtypes 
were significantly different (p<0.05).  
 
  
Results 
 
Mean patient age was 3.3 years (range 0.5-12.1 years), and the mean interval between pre- 
and post-chemotherapy scans was 46 days. None of the patients included in our cohort 
showed histological evidence of anaplasia.  
 
Example histological sections demonstrating the various elements (blastemal, epithelial, 
stromal and regressive) found within a WT are shown in Figure 2. These different cell types 
can all be found within a single WT. Overall, using the multi-Gaussian model we found that 
prior to chemotherapy, 51% of ADC histograms were best fit using 2 Gaussian distributions, 
29% were best fit with 3 Gaussians, and 20% were best fit with a single Gaussian. A similar 
pattern was observed post-chemotherapy, with 48%, 33% and 18% of tumours requiring for 
2, 3, and 1 Gaussian distributions respectively. In the lesions for which DWI data were 
available both pre- and post-chemotherapy (23 in total), the change in the number of fitted 
Gaussian components as a result of chemotherapy was as follows: -2: 4%, -1: 17%, 0: 38%, 
+1: 29% and +2: 12%. This indicates that in 38% of tumours, the number of ADC 
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subpopulations with distinct cellular density within the tumour tissue did not change as a 
result of chemotherapy. The mean r2 value for all multi-Gaussian fits was 0.97.   
 
The methodology described in section 2.4 was tested against the established EM algorithm 
for fitting Gaussian mixture models [22], [23]. The EM algorithm gave very similar results, 
with a mean difference of only 4.3% per tumour in the fitted value of ADC1LQ compared to 
our original analysis. However, the methodology presented here was found to be more 
stable, converging on exactly the same values over multiple iterations, whereas the EM 
algorithm was found to vary from one iteration to the next, with a mean variation of 2.5% in 
the calculated value of ADC1LQ across 10 iterations. Unlike the standard implementation of 
the EM algorithm, the methodology presented here places strict limits on the degree of 
overlap between the component Gaussian distributions, which ensures the fitted Gaussian 
components represent subpopulations with distinct cellularity. We believe this also 
contributes to the stability of the fitting process, and therefore this methodology was better 
suited to this study.     
  
 
ADC in viable/non-viable tissue 
 
The mean (±SEM) ADC value in all viable tumour tissue voxels across the cohort was (1.54 
± 0.0014) x10-3 mm2/s, compared to (1.98 ± 0.0025) x10-3 mm2/s in all necrotic tissue voxels 
(two tailed unpaired t-test, p<0.001). An ROC analysis, illustrated in Figure 3, determined the 
optimum upper threshold for viable tissue voxels to be ADCviable = 1.81x10
-3 mm2/s (67% 
sensitivity, 75% specificity, area under the curve = 0.72). An example of how this threshold 
can be used to identify sub-populations of non-viable tissue from the multi-Gaussian ADC 
model is shown in Figure 4. The green and blue coloured peaks in this example (Fig. 4E) 
were centred above ADCviable, and as such were identified as sub-populations of non-viable 
tissue (likely to be oedematous regions). This was further confirmed by the fact that these 
components of the ADC histogram were markedly reduced when the same tumour was 
analysed using the viable tissue mask (Fig. 4C). Furthermore, when comparing Fig. 4B and 
Fig. 4D it was clear that voxels belonging to these sub-populations (shown in green and blue 
in Fig. 4D) showed good visual correlation with the excluded regions from the viable tissue 
tumour mask (Fig. 4B), albeit with a slight discrepancy in places, which is discussed in 
section 4.1.  
 
Assessment of treatment response 
 
Example ADC histograms, before and after treatment, are shown for a representative patient 
in Figure 5. In this example, both pre- and post-chemotherapy, the multi-Gaussian model 
identified three sub-populations within the tumour. Prior to chemotherapy, the majority of the 
tumour tissue was described by a prominent sub-population with a low ADC value 
(ADC1MEAN = 6.7x10
-4 mm2/s, red in Fig 5C), representing highly cellular tissue, with another 
smaller peak in the ADC histogram centred at a value greater than ADCviable, (2.73x10
-3 
mm2/s, blue in Fig 5C), which is likely to represent oedematous, non-viable regions of the 
tumour. Between these peaks, a third subpopulation with a broad distribution of ADC values 
was observed, with a peak centred at 1.4 x10-3 mm2/s, which is likely to represent voxels 
containing a mixture of viable and oedematous tissue. Following chemotherapy, the centre 
of this broad central peak shifted slightly to the right. The high-ADC peak remained in the 
same position, with approximately the same height. The low-ADC peak remained centred on 
approximately the same value, but showed a marked decrease in height, indicating that 
chemotherapy had significantly reduced the volume of viable tumour tissue in this patient, 
but the cellular density of the viable tissue that remained was unchanged. Note this result 
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would be obscured if a single mean or median value for the entire ADC histogram were 
reported. 
 
Overall, the 23 tumours in which DWI data were available both pre- and post-chemotherapy 
consisted of the following histological subtypes (number of tumours in brackets): stromal (6), 
epithelial (4), blastemal (4), mixed (7), and regressive (2). Ladder plots of ADC1MEAN in these 
tumours, before and after chemotherapy, are shown in Figure 6. For each subtype, the mean 
(±SD) intra-tumour change in ADC1MEAN as a result of chemotherapy was: stromal: +68±42% 
(p=0.005, paired t-test), epithelial: +26±24% (p=0.12), blastemal: +5±27% (p=0.70), 
regressive: +120±102% (p=N/A, only 2 lesions), mixed: +63±72% (p=0.06). For each 
subtype, the mean (±SD) intra-tumour change in volume as a result of chemotherapy 
(determined by multiplying the number of voxels within the tumour ROI by the voxel volume) 
was: stromal: +15±61% (p=0.68), epithelial: -51±36% (p=0.15), blastemal: -62±29% 
(p=0.25), regressive: -54±56% (p=N/A (only 2 lesions)), mixed: -27±47% (p=0.28). 
 
 
Differentiation of Wilms tumour subtypes 
 
The 32 tumours for which post-chemotherapy ADC data were available comprised the 
following histological subtypes (number of tumours in brackets): stromal (6), regressive (5), 
mixed (11), epithelial (4), blastemal (5), completely necrotic (1). As there was only one 
completely necrotic tumour, this subtype was excluded from this part of the analysis. The 
results from ANOVA tests of both the multi-Gaussian parameters (ADC1MEAN, ADC1LQ) and 
raw histogram parameters (ADC0MEAN, ADC0LQ) across the WT subtypes are shown in Table 
1. Both ADC1MEAN and ADC1LQ were more effective at separating WT subtypes than their 
counterparts from the raw ADC histogram, and indeed no significant difference was 
observed between any WT subtypes using the mean of the raw ADC histogram (ADC0MEAN). 
The most significant difference between WT subtypes was found in the ADC1LQ parameter 
(ANOVA p=0.0004), and a box and whisker plot for this parameter is shown in Figure 7. 
Blastemal tumours had significantly lower ADC1LQ values than the stromal, regressive and 
mixed subtypes (p<0.05), but there was no significant difference between blastemal and 
epithelial lesions (p=0.35).  An ROC analysis indicted that the optimum ADC1LQ threshold 
value, in terms of differentiating epithelial and blastemal WTs (group 1) from the other 
subtypes (group 2), was 0.99x10-3 mm2/s (91% sensitivity, 89% specificity, area under curve 
= 0.81 – indicated by a horizontal line in Figure 7). Note, the tumour labeled ‘A’ in Figure 7, 
which was classified histologically as mixed, comprised 50% epithelial cells, 35% blastemal 
cells, and 15% stromal cells. So although this tumour was histologically referred to as mixed, 
the predominance of blastemal and stromal cells in the viable tissue explains the similarity 
between the ADC1LQ value in this tumour with the other epithelial/blastemal tumours. 
Similarly, the outlier from the mixed group with the high value of ADC1LQ (labeled ‘B’ in 
Figure 7) was classified histologically as mixed, with predominant widespread stromal 
elements. This may explain why the ADC1LQ value found in this lesion was more similar to 
the stromal group.   
 
Discussion 
 
Previous studies of chemotherapy response in WT have been largely based on 
histopathology, and as such it has not been possible to study the cellular composition of the 
same tumour at two time points. MRI provides a unique opportunity to measure 
morphological and functional changes in the same tumour over time. Conventionally, MRI 
has only been used to assess chemotherapy response by measuring the change in tumour 
volume. However, our data illustrate how chemotherapy-induced change in the cellularity of 
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tumour tissue can also be assessed, which is not correlated with a change in tumour 
volume.  
 
The most common subtype in our cohort was mixed (34% of tumours), followed by stromal, 
blastemal and regressive tumours (19%, 16%, and 16% respectively), epithelial (12%) and 
completely necrotic (3%). This shows a broadly similar pattern to the larger cohort studied by 
Weirich et al. [8], although in that study regressive was the most frequent subtype (after 
chemotherapy), and epithelial the least common. In Weirich et al.’s study, 71 patients who 
received immediate surgery without chemotherapy were also included, comprising 45% 
mixed, 39% blastemal and 16% epithelial WTs. The noticeable absence of stromal WTs in 
this group has been verified in other studies, which have reported very low incidences (<2%) 
of stromal WTs in immediately operated patients [6], [27]. Weirich et al. suggest that 
chemotherapy induces further differentiation and maturation of other subtypes into stromal 
predominant WTs. In our study, we were able to monitor the change in ADC (and therefore 
cellular density) as a result of chemotherapy in tumours classified as stromal after treatment.  
Our data support this hypothesis, since every stromal tumour in our cohort underwent a 
marked increase in ADC in the viable tissue as a result of chemotherapy. This suggests all 
these tumours were composed originally of tissue with a higher cellularity, such as immature 
blastema or stroma, which decreased significantly after chemotherapy, with the positive shift 
in ADC reflecting maturation into mature stromal tissue. Interestingly, this was not reflected 
in the change in tumour volume – despite a fairly uniform increase in ADC, 2 stromal 
tumours showed a marked increase in volume, 2 showed a very slight increase, and 2 
showed marked shrinkage as a result of chemotherapy.    
   
It has been suggested that blastema is the most responsive tumour component to 
chemotherapy [28], however WTs which remain predominantly blastemal after pre-operative 
chemotherapy are most likely to develop relapse [8].  We found that ADC1LQ was the best 
parameter for identifying blastemal-type WTs, with these having the lowest ADC1LQ values, 
suggesting the highest cellularity of all the subtypes. Of all the subtypes, our blastemal WTs 
also showed the greatest shrinkage in volume as a result of chemotherapy (mean -62% 
volume change), as well as the smallest chemotherapy-induced change in ADC1MEAN in the 
remaining viable tissue (mean 5% increase). This would confirm the hypothesis that 
blastemal cells are the most responsive to chemotherapy, represented by the high level of 
tumour shrinkage, but the viable tissue that remains following chemotherapy is chemo-
resistant, retaining a very low ADC value (high cellularity).     
 
All the epithelial WTs in our cohort showed a positive shift in ADC1MEAN as a result of 
chemotherapy, along with a shrinkage in volume. However, the shift in ADC1MEAN was small 
(only blastemal WTs showed a smaller increase), so, similar to blastemal WTs, 
chemotherapy was effective at shrinking epithelial WTs, but the remaining viable tissue was 
highly cellular.  
 
Although we only had pre- and post-chemotherapy DWI data for 2 regressive WTs, which 
precludes a statistical analysis of treatment response in this subtype, both of these 
regressive tumours showed a marked increase in ADC1MEAN as a result of chemotherapy, 
along with a small amount of tumour shrinkage. Regressive WTs often include regions of 
hypo-cellular tissue containing foamy and/or haemosiderin-laden macrophages [29]. The 
appearance of these hypo-cellular regions after chemotherapy is likely to be a major 
contributing factor to the large increase in ADC1MEAN values seen in these lesions.  
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Limitations 
 
The limited size of our cohort precludes a rigorous statistical analysis of chemotherapy 
response for each WT subtype. However, the primary aim of this study was to introduce the 
multi-Gaussian modelling approach to ADC histogram analysis, demonstrate its potential to 
identify the most prominent viable tissue sub-population in the tumour, and highlight the 
effect on the ADC values in this sub-population in high-risk WTs. Also, although our ADCviable 
threshold appears effective at removing non-viable oedematous tissue, ADC values in 
necrotic areas can occasionally be very low, mimicking highly cellular tumour tissue [2], and 
these will not be excluded in our analysis. Similarly, the slight discrepancy between the T1-
based viable tissue masks and the ADC maps, which tends to occur in regions that have 
high-ADC but are included within the viable tissue mask, could be due to partial volume 
artefacts in the DWI data. The T1-weighted data were acquired at a higher spatial resolution 
than the DWI data, and will be less susceptible to partial volume effects in voxels 
surrounding oedematous regions, hence non-viable regions on the viable tissue mask 
occasionally appear smaller in size. Furthermore, the threshold for viable tissue signal on the 
subtracted T1w images, based on the signal in the erector spinae muscles, may need further 
refinement, as occasionally voxels which show only marginal levels of enhancement on post-
Gadolinium T1w images may be incorrectly classified as viable tissue.  
 
Due to the rarity of anaplasia in WT (approx. 5% of patients), none of the patients in our 
cohort showed evidence of anaplasia on histological assessment, so the effect of this on 
ADC values could not be assessed. Also, although in-plane partial volume artefacts were 
minimised by only including tumours with an area greater than 3cm2, we were unable to 
account for through-plane partial volume artefacts.  Lastly, while ADC1LQ was effective at 
separating blastemal WTs from stromal, regressive and mixed subtypes, it could not 
separate blastemal and epithelial tumours. Both these subtypes contain highly cellular 
tissue, but only blastemal tumours are classified as ‘high-risk’. Further work is needed to 
separate these subtypes in vivo, perhaps using a larger cohort, combined with novel 
methods to register the source location of histology tissue samples onto ADC maps. 
Perfusion-weighted imaging may also help to differentiate these WT subtypes.  
 
Conclusion 
 
The ADC values provided by DWI provide a surrogate biomarker of cellular density, 
however, WTs are heterogeneous neoplasms, and it is clear that distinct cellular sub-
populations usually exist within a single tumour. Therefore, an overall mean or percentile 
ADC value obtained for the entire tumour will not give an accurate representation of tumour 
composition, as high ADC values in non-viable tissue regions will counteract low ADC values 
in highly cellular regions. Furthermore, distinct cellular regions within a tumour may respond 
differently to chemotherapy, so treatment response cannot be assessed reliably using 
summary ADC values for the entire tumour. The multi-Gaussian model presented here 
provides an automated means for representing a WT based on sub-populations with distinct 
cellularities, and identifying the predominant viable tissue sub-population, which will be 
closest matched to the tissue assessed by histological analysis. Using the multi-Gaussian 
model, the mean and lower quartile ADC values from the predominant viable sub-population 
are demonstrated to be better at differentiating histologically determined WT subtypes than 
the same metrics from the entire tumour, and can be used to separate highly cellular 
epithelial or blastemal predominant regions, from less cellular stromal, regressive and mixed 
regions. This information can be used to stratify patients based on the likely predominant cell 
type in a WT at an early stage, and could help surgeons target initial needle biopsies on 
more malignant tissue. Identifying regions which are more likely to contain malignant cells 
would also be helpful when planning nephron-sparing surgery, particularly in patients with 
bilateral WTs. 
 
11 
 
Lastly, there is emerging evidence that the current definition of ‘blatemal-type’ WT is 
somewhat subjective, as it does not measure the total volume of blastemal cells which 
survive chemotherapy, but rather the percentage of blastemal cells in the viable tissue. As 
such, a large WT classified as intermediate-risk may contain a greater absolute volume of 
blastemal cells than a smaller high-risk blastemal-type WT. A recent analysis has shown that 
there is a threshold for the total volume of blastemal cells that survive preoperative 
chemotherapy, of between 20-50 ml, that confers adverse event free survival, regardless of 
the histological classification of the WT [30]. However, total blastemal tissue volume is 
challenging to measure with histological techniques. By combining histological analysis of 
tumour tissue, which would remove the ambiguity between the predominance of blastemal / 
epithelial tissue, with an estimation of the total volume of low ADC tissue from the multi-
Gaussian model, an estimate of the total blastemal volume could be made. This would 
provide a new biomarker which would further refine the current clinical definition of ‘high-risk’ 
histology, and could be used to guide post-operative management of future WT patients. 
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Tables 
 
 
Table 1  
Results from ANOVA tests of multi-Gaussian and raw histogram parameters across Wilms’ 
tumour subtypes. 
 p-value 
(ANOVA) 
Significant differences (p<0.05, Tukey-Kramer) 
Multi-Gaussian 
analysis 
  
ADC1MEAN 0.0010 blastemal vs. stromal, blastemal vs. regressive, 
blastemal vs. mixed, epithelial vs. stromal 
ADC1LQ 0.00039 blastemal vs. stromal, blastemal vs. regressive, 
blastemal vs. mixed, epithelial vs. stromal 
Raw histogram   
ADC0MEAN 0.056 None 
ADC0LQ 0.0049 blastemal vs. stromal, epithelial vs. stromal 
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Figure Legends 
 
Figure 1  
(A) ADC map, with the Wilms tumour ROI outlined in blue, and (B) the ‘raw’ ADC histogram 
from this tumour. (C) The multi-Gaussian model provides a fitted curve to the histogram 
(white line), in this case comprising three underlying Gaussian distributions (shown in red, 
green and blue). The Mahalanobis distance (m) between the local ADC value and the three 
Gaussian components is calculated in each voxel in the tumour ROI, and normalised to the 
sum of all Mahalanobis distances in that voxel (mn). The red, green and blue channels of 
each tumour voxel in (D) represent 1- mn for the three Gaussian components shown in (C), 
with voxels closest to the lowest-ADC peak shown as red, those closest to the middle-ADC 
peak shown as green, and those closest to the highest-ADC peak shown as blue. 
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Figure 2 
 Histological sections demonstrating (A) blastemal, (B) epithelial, (C) stromal and (D) 
regressive tissue types within a Wilms’ tumour (haematoxylin and eosin stain, original 
magnifications x100, x100, x100 and x40 respectively).  
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Figure 3  
ROC curves, illustrating: (A) the optimum ADCviable threshold value, for differentiating viable 
(group 1) and non-viable (group 2) tissue, and (B) the optimum ADC1LQ threshold value, for 
differentiating epithelial and blastemal WTs (group 1) from the other subtypes (group 2).    
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Figure 4  
(A) T1w difference map (registered to DWI space), created by subtracting the pre-gadolinium 
signal intensity from the post-gadolinium signal, in a representative patient. The viable 
tumour tissue mask is shown in red in (B), and the ADC histogram for all voxels within this 
mask is shown in (C). The mapping of the sub-populations from the multi-Gaussian model is 
shown in (D), along with the ADC histogram and 3 underlying sub-populations in (E).  
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Figure 5  
ADC maps for a blastemal Wilms’ tumour patient pre- and post-chemotherapy are shown in 
(A) and (B) respectively, with voxels within the ROI coloured according to the Mahalanobis 
distance from each subpopulation (see Figure 1 for details). The corresponding ADC 
histograms are shown in (C) and (D) respectively, with the fit from the multi-Gaussian model 
overlaid.  
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Figure 6  
Ladder plots of ADC1MEAN in different Wilms’ tumour subtypes, with connected points 
representing the same tumour pre- and post-chemotherapy. A significant difference within 
each subtype between pre- and post-chemotherapy ADC1MEAN, determined using a two-
tailed paired t test, is indicated by * (p<0.05). No t test was performed on the regressive 
group (D) due to the small number of lesions in this group.  
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Figure 7 
 Box and whisker plot of ADC1LQ across Wilms’ tumour subtypes (post chemotherapy), with 
data points for individual tumours overlaid. Significant difference between blastemal tumours 
and all other subtypes, determined using an ANOVA / Tukey-Kramer posthoc test, is 
indicated by * (p<0.05). There was no significant difference between the epithelial and 
blastemal subtypes. The optimum ADC1LQ threshold value, in terms of differentiating 
epithelial and blastemal WTs (group 1) from the other subtypes (group 2), is overlaid 
(horizontal grey line at ADC1LQ=0.99x10
-3 mm2/s). The viable tissue in the tumour labelled ‘A’ 
was determined histologically to consist of 50% epithelial cells, 35% blastemal cells, and 
15% stromal cells. The tumour labelled ‘B’ was determined histologically to consist of 
widespread stromal elements.  
